Quest Diagnostics (DGX) Oct IV elevated at 43 into Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Quest Diagnostics (DGX) PT Lowered to $103 at Mizuho Securities
October 19, 2017 5:19 PM EDTMizuho Securities lowered its price target on Quest Diagnostics (NYSE: DGX) to $103.00 (from $122.00) while maintaining a Buy rating. Analyst Ann Hynes updated 2018 and 2019 adjusted EPS estimates, both decreasing by $0.10 related to the proposed PAMA rule released in September.
Mizuho Securities did not... More
